S-23

Intro

S-23 is an investigational nonsteroidal selective androgen receptor modulator originally studied as part of male hormonal contraception research.

In practical use it is treated as the most suppressive SARM lane: stronger than ostarine or andarine, more aggressive than LGD-4033 for HPTA shutdown, and close enough to oral-anabolic behavior that casual SARM framing becomes misleading.

The core tradeoff is simple. S-23 can produce a dry, hard, strength-forward look during a cut or lean-mass phase, but it does so by leaning heavily on androgen-receptor signaling. The corpus and community sources repeatedly describe major testosterone suppression, fertility disruption, and a need for full post-cycle recovery. That makes S-23 a poor beginner compound even though it is orally dosed.

Human bodybuilding data is thin. The strongest formal evidence is preclinical male-contraceptive/SARM pharmacology, while real-world protocol texture comes from community logs, forum dosing threads, and practitioner analysis. Treat every effect claim as self-experimenter evidence unless it is explicitly scoped to animal or in-vitro work.

Observed Effects

Strength and hardness. Users pursue S-23 for dry strength, dense muscle appearance, and lean-mass retention in a calorie deficit. Community protocols commonly discuss 10-30 mg/day, with 20 mg/day split morning/evening appearing as a common aggressive forum dose.

Cutting bias. S-23 is usually framed as better for cutting, hardening, or short strength phases than for comfortable bulking. Appetite, scale weight, and water retention are not the selling points; the appeal is androgenic drive without the wetter look associated with some other mass compounds.

Suppression is part of the effect profile. The same androgen-receptor potency that makes S-23 attractive is why users report it as one of the least forgiving SARMs. Low libido, low mood, fatigue, and poor recovery after stopping are expected failure modes when the user has no PCT or baseline labs.

Clinical transfer limit. Published human outcome data for physique use is not available. The practical effect profile is therefore a convergence of preclinical SARM design plus community use, not a controlled human trial result.

Field Reports

Community reports emphasize strength, dryness, and hardening more than scale-weight gain. Users often describe S-23 as visually effective during a cut, especially when calories, training, and leanness are already dialed in.

The negative reports cluster around suppression: libido drop, lethargy, mood flattening, poor post-cycle recovery, and anxiety about fertility. Some users compare it unfavorably with simply running testosterone because the side-effect management becomes similar while the evidence base is weaker.

Dose discussions often cite 10-20 mg/day as the common practical range, with 20 mg/day split AM/PM appearing in forum guidance. Reports above that range should be treated as aggressive self-experimentation, not a normal protocol.

Community Consensus

S-23 has a cult reputation because it sits at the edge of the SARM category. Advocates like the dry look, strength increase, and strong receptor feel.

Skeptics argue that once suppression, PCT, labs, and fertility risk are counted, the user has accepted steroid-like management for a less-studied unapproved compound.

The community split is not really about whether S-23 is strong. It is about whether the strength is worth the recovery burden. Beginner-oriented communities often steer users toward ostarine or away from SARMs entirely. Advanced SARM users describe S-23 as a tool for people who already know what shutdown feels like and can manage post-cycle recovery without guessing.

A recurring protocol theme is split dosing because oral-liquid products are commonly treated as daily compounds. Another recurring theme is full PCT. The users who minimize S-23 as just another SARM are the ones most likely to get surprised by the endocrine crash.

Risks & Monitoring

S-23's main risk is not injection logistics or novelty; it is endocrine suppression. Community and corpus evidence repeatedly frame it as a male-contraceptive-derived SARM that can drive testosterone, LH, and FSH down hard enough that recovery planning matters before the first dose.

Endocrine and fertility. Expect HPTA suppression in men, with fertility risk from reduced gonadotropin signaling and sperm-production pressure. Post-cycle symptoms can include low libido, erectile dysfunction, fatigue, irritability, depressive mood, and strength regression.

Lipids, liver, and cardiovascular markers. As an oral androgen-receptor modulator, S-23 belongs in the lipid/liver monitoring lane. HDL suppression, LDL rise, ALT/AST movement, and blood-pressure drift are the practical markers to watch. The absence of approved-drug labeling does not mean absence of risk.

Androgenic effects. Acne, oily skin, hair shedding in genetically susceptible users, irritability, and sleep disruption are plausible. Women face a higher consequence profile because voice, clitoral, and hairline changes can become irreversible.

Research-quality caveat. Many safety search hits were off-target IL-23, S223, or unrelated drug pages. The article therefore leans on class biology, SARM practice, and compound-specific community/corpus evidence rather than pretending there is a clean human safety package.

For Women

Monitoring Panels

Avoid With

Protocols By Goal

Cutting / hardening. Use the lowest dose that preserves training performance and gives the dry look; typically 10-20 mg/day in community practice. Keep the phase short, monitor lipids/liver markers, and do not confuse temporary hardness with keepable tissue gain.

Strength phase. S-23 can be used as a short strength-focused oral, but the cost is HPTA suppression. If the goal is maximal strength, compare against better-characterized testosterone or anabolic lanes rather than pretending S-23 is a mild supplement.

Lean-mass retention. The compound may help hold strength and lean tissue in a deficit, but the practical return depends on protein intake, training quality, sleep, and whether recovery after the cycle is handled.

Not a fertility-friendly protocol. Because the research origin and community framing both point to male-contraceptive pressure, avoid S-23 when near-term fertility matters.

Dosing Details

No approved human dosing protocol exists. Community use commonly clusters around 10-30 mg/day, usually oral liquid or capsules, for 6-8 weeks. A frequently cited aggressive community pattern is 20 mg/day split into 10 mg morning and 10 mg about 10-12 hours later.

Conservative exploratory use. 5-10 mg/day for 4-6 weeks is the lower-risk learning range. It is still suppressive and still needs baseline and post-cycle labs.

Common cutting protocol. 10-20 mg/day for 6-8 weeks, paired with resistance training and a calorie deficit. This is where users report the dry strength/hardness payoff.

Aggressive use. 20-30 mg/day for 8 weeks is advanced territory. The expected support cost rises quickly: lipids, liver enzymes, blood pressure, testosterone recovery, fertility risk, and PCT become the protocol rather than afterthoughts.

Do not run S-23 without a stop plan. If libido, mood, blood pressure, liver enzymes, or lipids move hard, the correct response is not to add more SARMs; it is to stop, retest, and recover.

Stacks & Alternatives

Advanced users sometimes pair suppressive SARMs with testosterone to avoid crashing androgen levels during the cycle. This moves the protocol into anabolic-cycle territory and requires full endocrine management.

Used by some cutting communities for endurance/lipid-adjacent goals without adding more androgen-receptor suppression. It carries its own risk debate and is not a safety antidote.

NAC/TUDCA-style liver support and lipid-focused diet/cardio are common support choices because oral androgenic compounds can move ALT/AST and HDL/LDL.

Alternatives

Stack Cost

Practical Setup

Form and handling. Most non-prescribed S-23 is sold as oral liquid or capsules. Concentration accuracy and product identity matter more with S-23 than with mild SARMs; products without recent third-party testing add avoidable risk.

Cycle length. Community cycles usually run 6-8 weeks. Longer use raises the recovery burden without reliable human data showing that the payoff keeps improving.

Budget. The compound is not the main cost. Baseline labs, post-cycle labs, PCT, blood-pressure tracking, and sourcing quality are the real budget.

Who should skip it. Beginners, women who are not deliberately accepting virilization risk, men trying to preserve fertility, users with poor HDL/LDL, elevated liver enzymes, uncontrolled blood pressure, untreated mood instability, or no plan for post-cycle recovery.

Mechanism Deep Dive

Selective androgen-receptor modulation. S-23 binds androgen receptors and produces anabolic signaling in muscle and bone while aiming for tissue selectivity versus classic anabolic-androgenic steroids.

In practice, tissue selectivity does not erase systemic androgen consequences.

Male-contraceptive pressure. The preclinical research context matters: S-23 was investigated in a hormonal male-contraception frame, where suppression of endogenous reproductive signaling is part of the pharmacologic profile. That is why community educators treat it as a shutdown compound rather than a light SARM.

Dry cosmetic profile. S-23 does not aromatize into estrogen, so users do not expect estrogenic water retention. The dry look can be appealing, but low-estrogen symptoms after suppression or poor recovery can still become a problem.

Oral androgenic burden. Oral exposure creates practical concern for liver enzymes and lipids. The mechanism is not identical to methylated oral steroids, but the monitoring lane is similar enough that ALT/AST and HDL/LDL should not be skipped.

Evidence Index